Qiming Venture Partners Founder: The "DeepSeek Moment" of China's Innovative Drugs
I'm PortAI, I can summarize articles.
Gary Rieschel, the founding managing partner of Qiming Venture Partners, believes that the Chinese biotechnology ecosystem is becoming increasingly 完善， and the "DeepSeek moment" may occur when AKESO's dual-specificity antibody, Ivosidenib (AK112), is launched and its efficacy is twice that of Keytruda
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Wallstreetcn The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments